The interactome of the Epstein-Barr virus nuclear antigen 5 suggests novel roles in RNA and protein metabolism by Ekholm, Josefine
The interactome of the Epstein-Barr virus nuclear antigen 5 
suggests novel roles in RNA and protein metabolism 
 
AKADEMISK AVHANDLING 
 
som för avläggande av medicine doktorsexamen vid Sahlgrenska 
akademin vid Göteborgs universitet kommer att offentligen försvaras i 
hörsal Hjärtat, Sahlgrenska universitetssjukhuset, 
fredagen den 5:e februari 2010, kl. 9:00 
 
av 
 
Josefine Ekholm 
 
Fakultetsopponent: Docent Laszlo Szekely 
Avdelningen för mikrobiologi, tumör och cellbiologi (MTC)  
Karolinska Institutet    
Stockholm, Sweden 
 
 
 
Avhandlingen baseras på följande arbeten: 
 
I. Epstein-Barr virus nuclear antigen 5 inhibits pre-mRNA cleavage and 
polyadenylation. 
Dufva, M., Flodin, J., Nerstedt, A., Rüetschi, U., and Rymo, L.  
Nucleic Acids Res. (2002) May;30(10):2131-2143  
 
II. Identification of intracellular proteins associated with the EBV-
encoded nuclear antigen 5 using an efficient TAP procedure and FT-
ICR mass spectrometry. 
Forsman, A., Rüetschi, U., Ekholm, J., and Rymo, L.  
Journal of Proteome Research (2008) Jun;7(6):2309-2319 
 
III. Epstein-Barr virus nuclear antigen 5 is a multi-functional protein 
with a possible role in the chaperone-mediated protein folding and 
ubiquitin-proteasome degradation systems.  
Ekholm, J., Forsman, A., Kashuba, E., Andersson, M. K., Rüetschi, U., 
and Rymo, L. 
In manuscript  
 
Keywords: Epstein-Barr virus, EBNA5, chaperone, proteasome, nucleolus 
ISBN 978-91-628-7999-0 
 
 
The interactome of the Epstein-Barr virus nuclear antigen 5 
suggests novel roles in RNA and protein metabolism 
 
Josefine Ekholm 
Institute of Biomedicine, University of Gothenburg, Sweden 
 
Epstein-Barr virus (EBV) is a human herpes virus that infects B and epithelial cells of the 
oropharynx. EBV is transmitted by saliva and establishes a lifelong latency in over 90% 
of the world's population. During latency, the virus exists predominantly as multicopy 
episomes in the nuclei of memory B cells. If these memory B cells are activated they can 
produce EBV virions and the person may shed the virus. Most people are exposed to the 
virus as children, when the disease produces no noticeable symptoms or only flu-like 
symptoms. Latent infection is associated with several malignancies, including Burkitt's 
lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and lymphoproliferative 
disorders in the immunosuppressed patients. A compromised immune system and an 
aberrant EBV latent gene expression are thought to play roles in the aetiology of EBV 
malignancies. EBV immortalizes human B cells through expression of at least 12 viral 
genes, which include the EBNA5 protein. Elucidation of EBNA5 functions has been 
guided by identification of interacting cellular and viral proteins. The functions of these 
cofactors implicate EBNA5 as a potential modulator of apoptosis, cell cycle processes, 
and transcriptional pathways. This thesis will add to the knowledge about how EBNA5 
contributes to EBV biology. By using luciferase and CAT as model proteins to study 
EBNA5-regulated gene expression in lymphoid cells, we found that EBNA5, at high but 
still biologically relevant levels, acted as a promiscuous repressor of gene expression from 
transfected plasmids. However, EBNA5 was more selective in the regulation of 
chromosomal genes; only two out of 588 human genes, thereof the pro-apoptotic BNIP3 
gene, were down-regulated. The decrease in expression from transfected plasmids was 
partly explained by the ability of EBNA5 to inhibit luciferase pre-mRNA 3´-end cleavage 
and polyadenylation. To gain further insight into molecular pathways in which EBNA5 
may have a regulatory role, we searched for cellular targets for EBNA5. By using an 
improved tandem affinity purification procedure, we identified 147 novel interaction 
partners of which 37 were validated with independent methods. The validated proteins 
could be grouped into three main classes depending on their biological function: I) protein 
folding and degradation, II) pre-mRNA processing, and III) ribosome biogenesis. We 
further showed that EBNA5 is part of high molecular complexes. Of particular interest, 
we verified interaction between EBNA5, Hsp70, and BAG2, a co-chaperone with the 
ability to inhibit ubiquitinylation, and as a consequence, protein degradation of Hsp70 
clients. Further studies on the effect of EBNA5 on luciferase activity demonstrated a 
correlation between luciferase activity and level of soluble luciferase protein. In addition, 
substantial amounts of insoluble luciferase had accumulated in the nuclei. Insolubilisation 
was accompanied by translocation of luciferase, EBNA5, Hsp70, and BAG2 to the 
nucleoli and to a small number of nuclear foci. An EBNA5 mutant (ΔCR3) was neither 
able to induce a similar translocation nor able to associate with BAG2. Therefore, we 
identified BAG2 as a major target of EBNA5. Moreover, over-expression of Hsp70 
blocked EBNA5-induced insolubilisation of luciferase. Our results indicate that EBNA5 
is likely to play a regulatory role in the decision between degradation and folding.  
 
